Register for BIO Partnering™ for Oncology to meet with prestigious organizations like these:

Qilu Pharmaceutical

Sean Xu

“We look forward to connecting with global partners at BIO Partnering for Oncology in Chicago during ASCO week. As one of the top three pharmaceutical companies in China, Qilu Pharmaceutical has built a robust pipeline with over 30 innovative oncology programs spanning IND-stage through Phase III clinical development. Our platforms include next-generation multi-specific antibodies and T-cell engagers, proprietary ADC technologies, innovative small molecules including inhibitors, PROTACs, and molecular glues, and emerging cell therapies. We are actively exploring global partnerships and out-licensing opportunities to accelerate the delivery of transformative therapies to patients worldwide.”

Shawn Xu, PhD, EMBA
VP, Business Development & Licensing
Head of Boston Innovation Center, Qilu Pharmaceutical

VCU Massey Comprehensive Cancer Center

Dr. Arup Bhattacharya“VCU Massey Comprehensive Cancer Center is seeking a partner for PEPD-G278D, a first-in-class protein that eliminates EGFR and HER2 at the source. It achieved 100% complete responses in Enhertu-resistant PDX models with no off-target toxicity. With a successful Pre-IND meeting completed, the program is now seeking a strategic partner to advance toward IND and first-in-human trials.”

Dr. Arup Bhattacharya, PhD
Research Scientist
Office of Clinical Transformation, Dept of Pharmacology & Toxicology
Massey Comprehensive Cancer Center

 

Blood Cancer United

Blaine Robinson“Blood Cancer United’s Therapy Acceleration Program (TAP) works hand in hand with the biotech community with a shared urgency to transform outcomes in blood cancers. During ASCO 2026, our partnering goal is to work with biotech innovators committed to advancing novel therapies to patients with greater speed and impact. Through strategic investment and partnership, TAP helps reduce development risk, accelerate progress, and deliver meaningful advances for the blood cancer community.”

Blaine Robinson, PhD
Vice President, Therapy Acceleration Program
Blood Cancer United

 

The University of Chicago

University of Chicago

“The University of Chicago has a world class research and medical center, including an NCI designated cancer center. During ASCO, we have many researchers sharing their translational work and are interested in engaging partners who are looking to expand their biotech IP portfolio. We also hope to build and grow clinical research collaborations, including meeting with service providers for our incubator space, as well as connecting with investors interested in early access to startups.”

Mike Hinton
Senior Manager, Business Development & Technology Marketing
The University of Chicago

 

BIO Partnering for Oncology is an independent event produced by BIO, the Biotechnology Innovation Organization, and is not affiliated with ASCO.